Press "Enter" to skip to content

Covaxin emergency use: WHO seeks ‘additional clarifications’ from Bharat Biotech

The World Health Organization (WHO) has requested further information in order to make a decision on Covid vaccine Covaxin’s much-anticipated Emergency Use Listing (EUL).

According to a source, the WHO Technical Advisory Group has requested more explanation from vaccine maker Bharat Biotech before deciding whether or not to award Covaxin EUL clearance.

In a meeting on Tuesday, the WHO’s Technical Advisory Group decided to do the final risk assessment after obtaining further data from the manufacturer.

Bharat Biotech, situated in Hyderabad, is due to submit the findings this weekend.

Watch | Covaxin: WHO to meet for emergency use listing

On November 3, the Technical Advisory Group may convene for the final risk-benefit analysis. 

The Technical Advisory Group for Emergency Use Listing (TAG-EUL) advises WHO on whether or not the COVID-19 vaccine should be listed for emergency use under the EUL protocol. 

Last week, the WHO stated that it is awaiting one more piece of information from Bharat Biotech on Covaxin and that it must properly analyse vaccines to verify their safety and that it “cannot take shortcuts” before endorsing one for emergency use.

The timing for the UN health agency’s Emergency Use Listing method is contingent on how soon a vaccine manufacturer can supply the data needed for WHO to assess the vaccine’s quality, safety, effectiveness, and appropriateness for low- and middle-income countries. 

(With inputs from agencies)

Source: Thanks WIONews.com